UK modernises gene therapy definition in regulatory revamp

News

The UK government has proposed changes to the definition of gene therapies and other genetic medicines, aiming to give developers greater clarity on the steps needed to bring them to patients.

The new legal definition of gene therapy medicinal products (GTMPs) will allow certain gene therapies and new genome-editing treatments to be regulated under the UK's established framework, according to the Medicines and Healthcare products Regulatory Agency (MHRA).

Among the changes to the definition is the removal of the "biological origin" requirement, meaning that synthetic GTMPs will now be covered, and the explicit addition of sequence-specific genome-editing therapies.

The MHRA and Department of Health in Northern Ireland sought public comment on proposals to update the definition, and the proposals were supported by 83% of respondents. Those included pharma and biotech companies, academic institutions, NHS organisations, patient groups, and professional bodies, according to the government's response (PDF) to the consultation.

The overall aim is to bring non-viral, synthetic RNA/DNA therapies and CRISPR and related genome editors under the advanced therapy medicinal product (ATMP) framework, instead of treating them as conventional medicines.

Industry groups, including the BioIndustry Association, welcomed the move to a mechanism-based definition, saying that it will give developers greater certainty, keep the UK competitive for clinical trials, and closely mirrors the EU's updated GTMP definitions in the pharma package, due to be fully implemented in 2028.

"Scientific advances are opening up new possibilities for innovative gene therapies, and it is important that regulation keeps pace," said MHRA executive director for operations, Julian Beach.

"These proposals will address a gap in the current definition, providing a clearer route to licensing for certain synthetic gene therapies and greater certainty for developers about the regulatory requirements they need to meet," he added.

Support for advanced manufacturing

The updated definition was showcased at the inaugural DIA-MHRA Global Summit in London, at which the regulator also announced AdvanceGxP, a service that will provide practical support to companies developing new technologies to manufacture medicines.

The service is being developed by the MHRA to help innovators address regulatory and quality questions earlier, reducing the risk of avoidable redesign and delays, and supporting more sustainable approaches – while also strengthening UK manufacturing.

The first phase of the programme is focusing on emerging challenges, such as "personalised treatments made at or near hospitals and clinics, manufacturing in space, and the use of AI, robotics and automation," according to the regulator.

Science, Innovation and Investment Minister, Chris McDonald, who announced AdvanceGxP at the DIA-MHRA meeting, said: "The UK is already a leader in life sciences research and, as new technologies enable rapid breakthroughs, we want to make sure that new treatments get to patients as soon as possible."